Coeliac disease

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Retrieved on: 
Wednesday, March 20, 2024
MERS, Patient, Ethics, Epidemic, NUC, Group 3, Clinical trial, Liver, Depreciation, Vaccine, Hepatitis, PD-1, Research, Coalition, Arbutus, Hepatology, Coeliac disease, Nivolumab, Safety, Immune system, CHB, Prostate cancer, CEPI, AASLD, University, Șaeș, Cancer, HBV, Conference, AstraZeneca, Autoimmunity, Infection, Human papillomavirus infection, Oxford University Innovation, SNAP, HPV, APOLLO, Pharmaceutical industry

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Key Points: 
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • We presented the final data in June 2023 at the European Association for the Study of the Liver Congress 2023 – The International Liver CongressTM.
  • We presented this data during an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023.
  • In November 2023, we announced the company’s renaming as Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
Monday, March 18, 2024
Inflammation, Health, Conference, Database, Patient, Serology, Research, Lymphocyte, Gastrointestinal disease, Doctor of Philosophy, CED, First wave, Abstract, Gastroenterology, DDW, Coeliac disease, IEL

BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024, in Washington, D.C.

Key Points: 
  • “The abstracts accepted for presentation at DDW 2024 showcase significant advancements in the field of gastroenterology, particularly in the precision diagnosis and management of celiac disease through the innovative VCIEL scale that our team has developed,” stated James Sapirstein, Chairman and CEO of First Wave BioPharma.
  • Details on the presentations are as follows:
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Tuesday, March 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

STATE OF CELIAC DISEASE IN CANADA - UNDERDIAGNOSED, UNAFFORDABLE AND UNSAFE FOOD: SURVEY

Retrieved on: 
Wednesday, February 28, 2024
Anxiety, Hospital, RISK, Restaurant, Genetic disorder, Radar, Diarrhea, Friends, Weight loss, Coeliac disease, Diabetic neuropathy, Federation, Malabsorption, Food, Increment, Risk, Frustration, HEALTH, Depression, Family, Headache, Disease, Migraine, Diagnosis, Child, Bloating, Brain, Dietary supplement

Twenty years after the first comprehensive survey of Canadians living with celiac disease, new results show the condition remains largely underdiagnosed, the gluten-free diet is often unaffordable, and many risk being exposed to unsafe food.

Key Points: 
  • Twenty years after the first comprehensive survey of Canadians living with celiac disease, new results show the condition remains largely underdiagnosed, the gluten-free diet is often unaffordable, and many risk being exposed to unsafe food.
  • Celiac Canada surveyed 7,500 Canadians with celiac disease on topics like what symptoms they experience, how long they went before being diagnosed, and how they manage living with the disease (eating challenges in social settings, the availability and cost of gluten-free food, and the psycho-social challenges of managing celiac disease).
  • Have all provinces add blood tests for celiac disease to the standard requisition used by family doctors.
  • Help healthcare professionals better recognize the increasing neurological and mental health signs of celiac disease (neuropathy, migraines, depression, anxiety) and not just the traditional disease symptoms (like bloating, weight loss, diarrhea).

Welcome to the Party! GOODLES Launches Long-Awaited Gluten-Free Mac and Cheese Line

Retrieved on: 
Tuesday, February 20, 2024
Mac, MAC, Veganism, Diet, Plant, OG, Whole Foods Market, Entrepreneurship, Cheese, Nutrient, Milk, Coeliac disease, Amazon, Taste, SRP, Nutritional science, Flour

SANTA CRUZ, Calif., Feb. 20, 2024 /PRNewswire/ -- GOODLES, the brand that reimagined mac and cheese, welcomes everyone to the party with the launch of its first gluten-free products – GLUTEN FREE VEGAN BE HEROES and GLUTEN FREE CHEDDY MAC – nutrient-packed and full of all the yum you'd expect with none of the gluten. Plus, like all GOODLES mac and cheese, they've got protein, fiber, prebiotics, and 21 nutrients from plants.

Key Points: 
  • Plus, like all GOODLES mac and cheese, they've got protein, fiber, prebiotics, and 21 nutrients from plants.
  • Fans have asked for gluten-free options since the brand launched, and now GOODLES has responded with, "Yes, chef!"
  • Over the last two years, the brand developed the perfect gluten-free mac that tastes like the OG and packs in the same key nutrients found in the core product line.
  • GLUTEN FREE VEGAN BE HEROES and GLUTEN FREE CHEDDY MAC are sold online at GOODLES.com and Amazon and in-store at Whole Foods.

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Retrieved on: 
Tuesday, January 30, 2024
JDRF, Primary biliary cholangitis, Bristol Myers Squibb, Immune system, Coeliac disease, Patient, Immune tolerance, T1D, Disease, Myasthenia gravis, Takeda Pharmaceutical Company, Vaccine

The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.

Key Points: 
  • The investment was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.
  • In connection with the financing, Benjamin “Beni” Rovinski, Ph.D., Managing Director of Lumira Ventures, and Simon Greenwood, Senior Investment Director of Roche Venture Fund, will join the COUR Board of Directors.
  • We believe COUR's proprietary and strongly differentiated platform is a versatile and first-in-class approach to meet this critical medical need.
  • We are dedicated to collaborating with COUR and its partners to help advance these potentially cutting-edge treatments for immune-related diseases.”

Celiac Disease Foundation Announces Three Senior-Level Appointments as Organization Expands in 2024

Retrieved on: 
Monday, January 8, 2024
Science, Research, Pharmaceutical, General Health, Health, Philanthropy, Fitness & Nutrition, Foundation, Hospital, Blood, Doctor of Philosophy, Coeliac disease, CDF, International Society, Innovation, Knowledge, MB, Community engagement, Social media, Growth, Patient, Diagnosis, Child, Environment, Nursing

The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, is expanding its operations with the appointment of three senior-level staff.

Key Points: 
  • The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, is expanding its operations with the appointment of three senior-level staff.
  • “This year will be one of tremendous growth for the Celiac Disease Foundation,” said Foundation CEO Marilyn G. Geller.
  • The recipient of the 2023 Celiac Disease Foundation Prize for Excellence in Celiac Disease Research , Dr. Anderson is distinguished in the field and has helped to cement the role of gluten-reactive T cells as the fundamental drivers of celiac disease.
  • His work was first to show that T cells specific for gluten circulate in celiac disease patients’ blood, confirming celiac disease is a systemic disease not limited to the gut.

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Retrieved on: 
Monday, December 18, 2023
Documentation, Gastrointestinal disease, Food, Malabsorption, FDA, Prevalence, Disease, Mortality, Stanford University, Inflammation, Coeliac disease, First wave, NIH, Patient, Therapy, Pharmaceutical industry

BOCA RATON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the company has signed a non-binding term sheet for a business combination with ImmunogenX, a clinical-stage biotherapeutics company developing Phase 3-ready latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease. Pursuant to the term sheet, First Wave BioPharma will acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple late-stage clinical assets, including latiglutenase and capeserod, which First Wave BioPharma recently in-licensed from Sanofi. Following consummation of the transaction, First Wave BioPharma will continue to trade on Nasdaq under the ticker symbol “FWBI”. The transaction, which has been approved by the Boards of Directors of both companies, is subject to the negotiation and execution of definitive documentation, approval of the stockholders of both First Wave BioPharma and ImmunogenX and other customary closing conditions and is expected to close in the first half of 2024.

Key Points: 
  • Pursuant to the term sheet, First Wave BioPharma will acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple late-stage clinical assets, including latiglutenase and capeserod, which First Wave BioPharma recently in-licensed from Sanofi.
  • Following consummation of the transaction, First Wave BioPharma will continue to trade on Nasdaq under the ticker symbol “FWBI”.
  • Operational and financial leadership positions will be comprised of current First Wave BioPharma executives, while clinical, regulatory affairs, and scientific positions will be led by executives of ImmunogenX.
  • Celiac disease is characterized by damage to the lining of the small intestine, causing malabsorption, gastrointestinal dysfunction and debilitating symptoms.

Celiac Disease Foundation Teams Up with Mark Cuban Cost Plus Drug Company

Retrieved on: 
Wednesday, December 6, 2023
Retail, Health, Other Retail, Fitness & Nutrition, General Health, Pharmaceutical, Policy, Cost Plus Drugs, Food, Pharmacist, Risk, Mortality, Cardiovascular disease, Patient, Multimedia, Respiratory disease, Private sector, World Market (store), Social media, Cancer, Diagnosis, Coeliac disease, Lymphoma, Dentistry

The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.

Key Points: 
  • The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.
  • We are pleased and proud to join forces with Mark Cuban Cost Plus Drug Company to provide peace of mind to our celiac disease community.”
    Cost Plus Drugs’ pharmacy fulfillment partners can address inquiries regarding gluten content in medications, ensuring that those with celiac disease can confidently navigate their needs with the guidance of knowledgeable pharmacists.
  • “We are thrilled to be working with the Celiac Disease Foundation,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • Living with celiac disease is a daily struggle, and it also increases the mortality risks for cancer, cardiovascular disease, and respiratory disease.